Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.
J RemonD IslaP GarridoJ de CastroM MajemN ViñolasA ArtalE CarcerenyM R García-CampeloP LianesM ProvencioO JuanP DizR BlancoR Lopez-CastroI MaestuC VadellJordi Remon MasipPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2017)
Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.